Russia Vaccine GMP Approval... EID and Etron Brighten Up

[Asia Economy Reporter Park Hyungsoo] The possibility of performance improvement for Korea Corus, invested by EID and ETRON, has increased.

On the 27th, according to EID and related industries, the Russian sovereign wealth fund RDIF announced on the official Sputnik vaccine website that Korea Corus has completed GMP approval for the production of the Sputnik vaccine. With the completion of GMP approval, the export of finished vaccine products is expected to be in full swing.

Korea Corus signed a supply contract with RDIF for approximately 150 million doses of the Sputnik V vaccine. Currently, 10 million doses of vaccine bulk have been produced, and the initial shipment is expected to be between 6 to 7 million doses.

Korea Corus is the first case outside Russia to receive GMP approval for the production of the Sputnik vaccine. Korea Corus is preparing for an IPO with Kiwoom Securities as the lead underwriter. As the production of the Sputnik vaccine accelerates, the listing process is also expected to gain momentum.

The Russian government plans to outsource the production of more than 1 billion doses of the Sputnik vaccine annually through global partners outside Russia. Currently, the Sputnik vaccine has been approved for vaccination in more than 15 countries, and an additional 30 countries are reportedly undergoing procedures for vaccine approval.

Korea Corus is also promoting the production of Sputnik Light, a single-dose COVID-19 vaccine, in addition to Sputnik V. To this end, a Sputnik vaccine contract manufacturing consortium has been formed, centered on domestic pharmaceutical and bio companies such as Isu Abxis, Chong Kun Dang Bio, and Zetema.

This content was produced with the assistance of AI translation services.